Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination

    loading  Checking for direct PDF access through Ovid

Abstract

Accumulating evidence demonstrates the importance of CD4+ T cells in antitumor immune responses. Identifying promiscuous MHC class II-binding peptides derived from relevant tumor-associated antigens that specifically target CD4+ helper T cells in vivo represent a powerful approach to fully exploit these cells for anticancer immunotherapy.

Related Topics

    loading  Loading Related Articles